Orthofix Medical Hits 52-Week Low at $9.14 Amid Market Challenges

Orthofix Medical, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 9.14 on June 15, 2026. This decline marks a significant downturn for the company, which has seen its stock price fluctuate considerably over the past year, with a 52-week high of USD 16.99. Despite the recent price drop, Orthofix Medical has reported some positive financial metrics. The company achieved its highest operating cash flow of USD 35.17 million in March, alongside a notable reduction in raw material costs, which fell by 30.75% year-over-year. However, the company continues to face challenges, as indicated by a return on equity of -20.74% and a consistent underperformance against the S&P 500 over the last three years. With a market capitalization of USD 462 million and a debt-to-equity ratio of 0.17, Orthofix Medical's financial position reflects a cautious outlook. The stock's performance has generated a return of -16.58% over the past year, highlighting the volatility and risks associated with its current market standing.